The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy

Peter Aaby,1,2 Cesário L Martins,1 May-Lill Garly,1 Amabelia Rodrigues,1 Christine S Benn,1,2 Hilton Whittle3


ABSTRACT

Objective: The current policy of measles vaccination at 9 months of age was decided in the mid-1970s. The policy was not tested for impact on child survival but was based on studies of seroconversion after measles vaccination at different ages. The authors examined the empirical evidence for the six underlying assumptions.

Design: Secondary analysis.

Data sources and methods: These assumptions have not been research issues. Hence, the authors examined case reports to assess the empirical evidence for the original assumptions. The authors used existing reviews, and in December 2011, the authors made a PubMed search for relevant papers. The title and abstract of papers in English, French, Portuguese, Spanish, German and Scandinavian languages were assessed to ascertain whether the paper was potentially relevant. Based on cumulative measles incidence figures, the authors calculated how many measles cases had been prevented assuming everybody was vaccinated at a specific age, how many ‘vaccine failures’ would occur after the age of vaccination and how many cases would occur before the specific age of vaccination. In the combined analyses of several studies, the authors used the Mantel–Haenszel weighted RR stratifying for study or age groups to estimate common trends.

Setting and participants: African community studies of measles infection.

Primary and secondary outcomes: Consistency between assumptions and empirical evidence and the predicted effect on mortality.

Results: In retrospect, the major assumptions were based on false premises. First, in the single study examining this point, seronegative vaccinated children had considerable protection against measles infection. Second, in 18 community studies, vaccinated measles cases (‘vaccine failures’) had threefold lower case death than unvaccinated cases. Third, in 24 community studies, infants had twofold higher case death than older measles cases. Fourth, the only study examining the assumption that ‘vaccine failures’ lead to lack of confidence found the opposite because vaccinated children had milder measles infection. Fifth, a one-dose policy was recommended. However, the two randomised trials of early two-dose measles vaccination compared with one-dose vaccination found significantly reduced mortality until 3 years of age. Thus, current evidence suggests that the optimal age for a single dose of measles vaccine should have been 6 or 7 months resulting in fewer severe unvaccinated...
cases among infants but more mild ‘vaccine failures’ among older children. Furthermore, the two-dose trials indicate that measles vaccine reduces mortality from other causes than measles infection.

Conclusions: Many lives may have been lost by not determining the optimal age of measles vaccination. Since seroconversion continues to be the basis for policy, the current recommendation is to increase the age of measles vaccination to 12 months in countries with limited measles transmission. This policy may lead to an increase in child mortality.

INTRODUCTION

With the spectacular success in measles control in the last 10–15 years and the current policy to move ahead with elimination and eventually eradication of measles infection, there is now a discussion of when to introduce the second dose of measles vaccine (MV). However, few people realise that the key policy of vaccinating against measles at 9 months of age in low-income countries is not based on evidence documenting the optimal age of measles vaccination to reduce overall child mortality.

In the 1970s, policy makers found it necessary to formulate a common policy for low-income countries since many donors and scientists at the time questioned the value of measles vaccination. Measles infection was believed to kill mainly malnourished children likely to die of other infections if not from measles and hence some people thought that MV would not red health overall mortality, but merely change the cause of death. The policy makers’ definition of the optimal age of measles vaccination of 9 months was based on a number of assumptions. Though these assumptions for vaccinating at age 9 months were not subsequently substantiated, the policy has remained in effect. Recently, though, it has been recommended that primary measles vaccination should be at 12 months of age in countries where measles infection has been controlled.

In the first measles vaccination campaigns in West and Central Africa in the 1960s, children were targeted from 6 months of age. Initially it was thought that it would be sufficient to conduct campaigns every second or third year to control measles. However, the epidemiologists soon learnt that shorter intervals of 6 or 12 months between campaigns were necessary to control measles. In the 1970s, routine vaccination programmes were introduced and the optimal age of routine measles vaccination was debated. Following the experience with the campaigns, several African countries recommended measles vaccination at 6, 7 or 8 months of age. A study sponsored by the Ministry of Health in Kenya and WHO assessed the seroconversion rates at different ages between 5 and 12 months and recommended measles vaccination at 7½ months of age. For several years, MV was administered at 8 months of age in Kenya. Similar studies of seroconversion were conducted in Latin America. Since some of those vaccinated at 6 months were not protected, some countries and many researchers recommended a second dose at 9 months of age or later. However, there were fears that early vaccination would produce too many vaccine failures and a one-dose programme was considered necessary because mothers would not bring their children back for a second dose. Therefore, the Expanded Programme on Immunization (EPI) recommended a one-dose policy. In 1980, the Global Advisory Group of EPI endorsed this policy and recommended measles vaccination as early as possible after 9 months of age.

Before the global policy is changed to 12 months of age, it is timely to examine the empirical basis for the assumptions underlying the current policy. Since these assumptions have not been research issues, we have had to use a search strategy including review articles and case reports to assess the validity of the original assumptions. The present analysis suggests that in retrospect, all assumptions were flawed. Had the policy been tested in randomised trials measuring the impact on mortality of vaccination at different ages, it is likely that the age of measles vaccination had been changed, with the result that the measles vaccination programme would have had a much larger effect on child survival in low-income countries.

METHODS

The optimal age of measles immunisation: the underlying assumptions

The recommendation was based on the belief that the expected reduction in mortality could be computed from seroconversion rates and the policy was justified several times by analyses of the seroconversion data from Kenya. In these analyses, it was assumed that seroconversion was associated with full protection against measles infection (assumption 1) and that non-seroconversion was associated with full susceptibility to measles infection (assumption 2). As shown in table 1 (column 2), the data from Kenya showed that seroconversion increased with age. This was not unexpected since the calculation of this measure (a fourfold or more increase over baseline) is dependent on level of maternal antibody, which wanes as the child ages. Based on cumulative measles incidence figures (column 1), it was calculated how many measles cases had been prevented assuming everybody was vaccinated at a specific age (column 3), how many ‘vaccine failures’ would occur after the age of vaccination (column 4) and how many cases would occur before the specific age of vaccination (column 5). In making these calculations, it was assumed that ‘vaccine failures’ and unvaccinated measles cases were equally severe (assumption 3) and that it did not matter whether measles was acquired in infancy or later in childhood (assumption 4). Vaccination at 8, 9 and 10 months of age prevented roughly the same proportion of cases between 79% and 84% (column 3). Vaccination at 8 months resulted in considerably more
Table 1  Projected reduction in measles cases and measles deaths with measles immunisation at ages 4–10 months, Machakos, Kenya 1974–1981

<table>
<thead>
<tr>
<th>Expanded programme on immunisation model8</th>
<th>Column 1</th>
<th>Column 2</th>
<th>Column 3</th>
<th>Column 4</th>
<th>Column 5</th>
<th>Column 6</th>
<th>Column 7</th>
<th>Column 8</th>
<th>Column 9</th>
<th>Column 10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cumulative measles incidence (%)</td>
<td>Seroconversion from MV (%)</td>
<td>Prevented cases (%)</td>
<td>Vaccine failures (%)</td>
<td>Cases prior to MV (%)</td>
<td>EPI assumption: case death (%)</td>
<td>Adjusting vaccination status and age of infection (%)</td>
<td>Adjusting vaccination status and age of infection (%)</td>
<td>Adjusting vaccination status and age of infection (%)</td>
<td>Adjusting vaccination status and age of infection (%)</td>
</tr>
<tr>
<td>Age 4 months</td>
<td>0.5</td>
<td>15</td>
<td>15</td>
<td>85</td>
<td>0</td>
<td>34</td>
<td>11.3</td>
<td>11.3</td>
<td>5.7</td>
<td>8.5</td>
</tr>
<tr>
<td>Age 5 months</td>
<td>1.0</td>
<td>35</td>
<td>35</td>
<td>65</td>
<td>0</td>
<td>26</td>
<td>8.6</td>
<td>8.6</td>
<td>4.3</td>
<td>6.5</td>
</tr>
<tr>
<td>Age 6 months</td>
<td>2.8</td>
<td>52</td>
<td>51</td>
<td>48</td>
<td>1</td>
<td>19.6</td>
<td>6.8</td>
<td>7.2</td>
<td>4.0</td>
<td>5.6</td>
</tr>
<tr>
<td>Age 7 months</td>
<td>6.1</td>
<td>72</td>
<td>69</td>
<td>28</td>
<td>3</td>
<td>12.4</td>
<td>4.9</td>
<td>6.1</td>
<td>4.3</td>
<td>5.2</td>
</tr>
<tr>
<td>Age 8 months</td>
<td>9.5</td>
<td>86</td>
<td>79</td>
<td>15</td>
<td>6</td>
<td>8.4</td>
<td>4.4</td>
<td>6.8</td>
<td>5.8</td>
<td>6.3</td>
</tr>
<tr>
<td>Age 9 months</td>
<td>14.4</td>
<td>95</td>
<td>84</td>
<td>7</td>
<td>9</td>
<td>6.4</td>
<td>4.5</td>
<td>8.1</td>
<td>7.7</td>
<td>7.9</td>
</tr>
<tr>
<td>Age 10 months</td>
<td>18.6</td>
<td>98</td>
<td>82</td>
<td>4</td>
<td>14</td>
<td>7.2</td>
<td>6.1</td>
<td>11.7</td>
<td>11.5</td>
<td>11.6</td>
</tr>
</tbody>
</table>

Bold and italic mark the month of vaccination with the lowest measles mortality given the set of assumptions specified for a specific column.

The estimated number of measles deaths was obtained by multiplying the number of vaccine failures (column 4) and cases prior to MV (column 5) in a cohort of 1000 children by the case death rates as indicated in the following notes:

*Assumption: the relative case death ratio is 1/3 for vaccinated versus unvaccinated cases, that is, 4% for unvaccinated cases and 1.33% for vaccinated cases.

†Assumption: the relative case death ratio is 1/3 for vaccinated versus unvaccinated cases. The case death ratio is twice as high for unvaccinated cases occurring in infancy. Hence, the estimated case death ratios are 8% for unvaccinated cases occurring in infancy and 1.33% for vaccinated cases.

‡Assumption: seronegative children had 50% or 25% protection against measles. Hence, the estimated case death ratios are 8% for unvaccinated cases occurring in infancy and 1.33% for vaccinated cases, but there were fewer vaccinated cases than indicated in column 4.

EPI: Expanded Programme on Immunization, MV, measles vaccine.
vaccine failures (15%) than that at 9 months (7%). Since vaccine failures were assumed to jeopardise the credibility of the measles immunisation programme (assumption 5), it was concluded that the optimal age for administration of MV would be 9 months. At the time, the EPI assumed that the case death in measles infection was 4% in Africa, and it will be seen in column 6 that the number of estimated measles deaths in a birth cohort of 1000 children would indeed be lowest (between 6.4 and 8.4) for vaccination at 8–10 months of age. In making this analysis of the effect of only one dose of MV, the EPI assumed that a two-dose policy was not feasible or unjustified (assumption 6).

Selection of studies
Following the identification of the underlying assumptions, we looked for empirical evidence in community studies to support or refute their validity. The original policy was mainly justified in relation to the epidemiology of measles infection in Africa where the case death was clearly higher than in other regions. Most community studies of measles infection are indeed from Africa and we have therefore restricted the analyses and tables 2–4 to the African studies. These tables are believed to be exhaustive for Africa, and they are not contradicted by community studies from Latin America and Asia. For the analysis of the impact of measles vaccination on child mortality, we included all studies from Africa and we included all studies from Asia and Latin America.

Since there are few specific studies to test the six assumptions, we have had to use case reports of measles outbreaks to assess their validity. Over the last 20–25 years, several reviews of community studies of the measles case death compiled studies of relevance for particularly assumptions 3 and 4, two of these being by the first author (PA). For each assumption, we used existing reviews, and in December 2011, the first author made a PubMed search for relevant papers as described below. The title and abstract of papers in English, French, Portuguese, Spanish, German and Scandinavian languages were assessed by the first author to ascertain whether the paper was potentially relevant. Potentially relevant papers were read. Most papers were not from Africa but were reviews or case reports and not community-based studies and had no information on mortality. We included one unpublished report from a large epidemic in Bissau in 1991–1992, which has remained unpublished because the physician (Henning Andersen) handling the epidemic died tragically in an accident shortly after the epidemic.

We distinguished between prospective community studies and surveys retrospectively assessing events since the precision of information on vaccination status and age presumably is better in prospective studies. Though hospital and health centre studies may have data on the severity of measles infection by vaccination status or age, we have not included these studies in the analysis since biased admission for some groups might have made the result non-representative.

Since the analysis of the assumptions suggested that measles vaccination before 9 months of age could be beneficial, we assessed the empirical evidence from studies, which assessed the effect of early measles vaccination on mortality. Again, we used all reviews of community studies and trials assessing the impact of measles vaccination on child mortality. Additional PubMed searches for studies comparing the mortality of measles-vaccinated and measles-unvaccinated children did not identify further studies. As explained in the footnote to table 5, we have emphasised the studies in which inactivated vaccines were not administered simultaneously with MV or after MV as such combination or sequences can have a negative effect on child survival.

Presentation
For each assumption, we briefly outline the background. Next, we present the relevant studies found and then analyse the common trends, identifying the secondary analyses, which have been made. Finally, we considered whether methodological issues and data quality might question the trends suggested by the analysis.

Statistical analyses
Based on cumulative measles incidence data, we calculated how many measles cases and measles death had been prevented assuming everybody was vaccinated at a specific age, how many ‘vaccine failures’ would occur after the age of vaccination and how many cases would occur before the specific age of vaccination. It was estimated how this calculation was influenced by the empirical evidence for the underlying assumptions. In the combined analyses of several studies, we used the Mantel–Haenszel (MH) weighted RR stratifying for study or age groups to estimate common trends.

Ethics
Since the study is a secondary analysis of existing data, approval from an ethical committee was not needed.

RESULTS
Assumption 1: children who seroconvert to MV have absolute protection against measles infection
Background
It has usually been assumed that previous measles infection is associated with lifelong immunity. This idea was transferred to measles vaccination when the vaccine was developed in the 1950s. Hence, if someone had antibodies after vaccination, these were also assumed to provide lifelong protection.

Data
We searched for ‘measles infection seropositive vaccinated children’ (N=12) and ‘measles vaccine failure’ (N=318). There are many case reports that contradict that seroconverted children have absolute protection but no African community study.
A number of smaller studies have documented that a few children do get measles after having seroconverted. Hence, seroconversion does not give absolute protection.

However, there are no general epidemiological studies from Africa and it is therefore difficult to estimate the proportion of children who get measles in spite of having seroconverted but since no large series have been reported, it is likely to be small.

Assumption 2: vaccinated children who are seronegative are fully susceptible to measles infection

Background

Measles immunity has generally been considered an either—or phenomenon. If a vaccinated child was seronegative, it was assumed that the child was fully susceptible.

Data

We searched for ‘measles infection seronegative vaccinated children’ (N=13) and ‘measles vaccine failure’ (N=318). This provided only one relevant reference.

Analysis

In a study in Senegal, vaccinated children who were seronegative when exposed to measles infection at home had a 49% (95% CI 21% to 68%) protection against clinical disease compared with unvaccinated seronegative children exposed under similar conditions.

Considerations

Apparently, no other study has tested the susceptibility of vaccinated ‘seronegative’ children. It is possible that some children had acquired vaccine-induced measles immunity.

Table 2: Acute measles case death ratio for measles-vaccinated and measles-unvaccinated cases in African prospective community studies and community surveys

<table>
<thead>
<tr>
<th>Country</th>
<th>Period</th>
<th>Study</th>
<th>Vaccinated cases, % (deaths/cases)</th>
<th>Unvaccinated cases, % (deaths/cases)</th>
<th>Measles case death ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bissau</td>
<td>1980–1982</td>
<td>PCS; urban</td>
<td>9 (5/53)</td>
<td>17 (18/108)</td>
<td>0.58 (0.23–1.49)*</td>
</tr>
<tr>
<td>Bissau</td>
<td>1980–1982</td>
<td>PCS; urban</td>
<td>14 (3/21)</td>
<td>46 (11/24)</td>
<td>0.30 (0.10–0.86)*</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>1983–1984</td>
<td>PCS; urban</td>
<td>4 (4/90)</td>
<td>9 (21/234)</td>
<td>0.41 (0.14–1.22)*</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>1984–1987</td>
<td>PCS; 2-year follow-up</td>
<td>0 (0/4)</td>
<td>13 (2/16)</td>
<td>0 (0–23.10)</td>
</tr>
<tr>
<td>Bissau</td>
<td>1985–1987</td>
<td>PCS; children &lt;2 years; urban</td>
<td>5 (1/22)</td>
<td>11 (10/90)</td>
<td>0.41 (0.06–3.03)†</td>
</tr>
<tr>
<td>Bissau (unpublished)</td>
<td>1991</td>
<td>PCS; children &lt;10 years; urban</td>
<td>2 (10/412)</td>
<td>13 (64/478)</td>
<td>0.24 (0.12–0.49)*</td>
</tr>
<tr>
<td>Senegal</td>
<td>1987–1994</td>
<td>PCS; rural</td>
<td>0 (0/127)</td>
<td>2 (18/1085)</td>
<td>0 (0–1.94)*</td>
</tr>
<tr>
<td>Ghana</td>
<td>1989–1991</td>
<td>PCS; rural; vitamin A trial</td>
<td>10 (15/153)</td>
<td>17 (136/808)</td>
<td>OR=0.42 (0.21–0.83)§</td>
</tr>
<tr>
<td>Kenya</td>
<td>1986</td>
<td>SUR; all ages; rural</td>
<td>2 (2/41)</td>
<td>11 (11/98)</td>
<td>0.51 (0.08–3.08)*</td>
</tr>
<tr>
<td>Kenya</td>
<td>1988</td>
<td>SUR; children &lt;5 years; rural</td>
<td>0 (0/23)</td>
<td>10 (18/182)</td>
<td>0 (0–1.54)*</td>
</tr>
<tr>
<td>Chad</td>
<td>1993</td>
<td>SUR; rural</td>
<td>0 (0/23)</td>
<td>8 (61/801)</td>
<td>0 (0–2.18)</td>
</tr>
<tr>
<td>Niger</td>
<td>2003–2004</td>
<td>SUR**; urban</td>
<td>0.4 (1/286)</td>
<td>6 (29/481)</td>
<td>0.06 (0.01–0.42)</td>
</tr>
<tr>
<td>Chad</td>
<td>2004–2005</td>
<td>SUR**; urban</td>
<td>0.4 (2/494)</td>
<td>8 (18/212)</td>
<td>0.05 (0.01–0.20)</td>
</tr>
<tr>
<td>Nigeria</td>
<td>2004–2005</td>
<td>SUR**; rural</td>
<td>9 (1/111)</td>
<td>7 (79/1131)</td>
<td>1.30 (0.20–8.54)</td>
</tr>
<tr>
<td>Sudan</td>
<td>2004</td>
<td>SUR</td>
<td>0.4 (2/556)</td>
<td>1 (7/568)</td>
<td>0.29 (0.06–1.40)</td>
</tr>
<tr>
<td>Niger</td>
<td>1991–1992</td>
<td>SUR; rural</td>
<td>17 (20/118)</td>
<td>15 (61/410)</td>
<td>1.14 (0.72–1.81)</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>1980–1989</td>
<td>SUR; urban</td>
<td>2 (8/335)</td>
<td>7 (20/302)</td>
<td>0.36 (0.16–0.81)</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>9 (55/2753)</td>
<td>10 (18/182)</td>
<td>0.39 (0.31–0.49)</td>
</tr>
</tbody>
</table>

Sources: Reviews of measles case death studies and PubMed search for measles mortality/case death in vaccinated children; compiled by Henning Andersen shortly before he died.

* Adjusted for age.
† Mortality is high because only secondary cases are included in the analysis. Since this analysis is a subgroup within the larger study, it has not been included in the combined estimate.
‡ Adjusted for district.
§ Case death ratio calculated by the authors, the remaining studies have been calculated by us.
* Adjusted for age, sex, weight-for-age z-score, paternal education and season.
** Mortality was only reported for children with at least 30 days of follow-up, whereas the proportion of vaccinated was reported among all cases. It has been assumed that the proportion of vaccinated cases was the same among those with follow-up as among all cases.
PCS, prospective community studies; SUR, community surveys or outbreak investigations.

Analysis

A number of smaller studies have documented that a few children do get measles after having seroconverted. Hence, seroconversion does not give absolute protection.

Considerations

However, there are no general epidemiological studies from Africa and it is therefore difficult to estimate the proportion of children who get measles in spite of having seroconverted but since no large series have been reported, it is likely to be small.

Assumption 2: vaccinated children who are seronegative are fully susceptible to measles infection

Background

Measles immunity has generally been considered an either—or phenomenon. If a vaccinated child was seronegative, it was assumed that the child was fully susceptible.

Data

We searched for ‘measles infection seronegative vaccinated children’ (N=13) and ‘measles vaccine failure’ (N=318). This provided only one relevant reference.

Analysis

In a study in Senegal, vaccinated children who were seronegative when exposed to measles infection at home had a 49% (95% CI 21% to 68%) protection against clinical disease compared with unvaccinated seronegative children exposed under similar conditions.

Considerations

Apparently, no other study has tested the susceptibility of vaccinated ‘seronegative’ children. It is possible that some children had acquired vaccine-induced measles immunity.

antibodies earlier but subsequently lost them. Cellular immunity may be obtained without having measurable antibodies.72 There is also good evidence from studies of hepatitis B vaccination that antibody concentration wane with time but the majority of older seronegative children if infected are protected from chronic carriage and its damaging consequences.73

The concept of seroconversion to compare the effect of vaccination at different age is in itself problematic. Seroconversion is not the same as serum protection and the use of the term inevitably disadvantages data from studies that have vaccinated at earlier ages when maternal antibodies are still present. Thus, a child immunised at 6 months of age when the maternal antibody level is about 62.5 mIU may fail the test for conversion (a fourfold increase) yet still have a protective level of 125 mIU at 9 months of age.

If approximately half the seronegative children have clinical protection, it would have major consequences for the calculation of the optimal age of MV.

**Assumption 3: severity of measles infection in vaccinated children (‘vaccine failures’) and unvaccinated children is the same**

**Background**

The EPI perceived ‘vaccine failures’ as due to the vaccine being inactivated by improper storage and handling or due to neutralisation of the vaccine by maternal antibodies.16 19 Hence, it was assumed that these children had been fully susceptible to measles infection. However, many epidemiological studies in the 1980s and 1990s suggested that measles-vaccinated children who contracted measles infection had milder disease.32 48 This would suggest that the children had partial measles immunity, not enough to protect them but enough to modify the severity of the disease.

**Data**

We searched for ‘measles mortality vaccinated children’ (N=143), ‘measles vaccine mortality’ (N=775), ‘measles case fatality’ (N=161) and ‘measles vaccine failure’ (N=318). The 18 relevant studies are included in tables 2 and 3.

**Analysis**

The community studies of the acute measles case death are shown in table 2. Only two African studies32 37 have reported significant differences in mortality for vaccinated and unvaccinated measles cases. A combined analysis has not been made previously. The measles case death was two to fivefold lower for vaccinated children (‘vaccine failures’) than for unvaccinated children with measles infection in nearly all studies. Using MH weighted RR, the effect was similar in the prospective community studies (case death ratio=0.37 (95% CI: 0.27–0.52)) and the retrospective surveys (case death ratio=0.41 (0.29–0.56)).

A few studies followed the children for longer than 1 month, which is the normal time limit for acute measles deaths. The long-term trend was the same with considerable better survival among vaccinated than among unvaccinated children after measles infection (table 3). Combining the prospective community studies in tables 2 and 3 would suggest a threefold reduction in acute and/or long-term mortality among vaccinated children, even though some of the vaccine failures may have been due to inactivated MVs.

In the four studies (38 47 56 unpublished) with information on both acute and long-term mortality, mortality was nearly fivefold lower for the vaccinated cases (MH weighted mortality ratio=0.21 (0.13–0.34)).

**Considerations**

Only two studies did not show lower case death among vaccinated children, and five of the 18 studies in tables 2 and 3 showed significantly lower mortality among vaccinated children.

All studies with relevant data were included in tables 2 and 3 irrespective of whether vaccine efficacy (VE) against measles infection was high or substandard. In
several studies, the VE was not high, but nonetheless, the vaccine appeared to have had an effect; for example, in Kenya, VE was only 18% but measles-vaccinated children had still twofold lower measles mortality than measles-unvaccinated children (table 2). Only one community survey from Niger reported that MV was not particularly effective against measles infection. It could be speculated that vaccinated children had more health-system-compliant mothers and that they therefore had more care and milder infection. However, in many of the original studies from the 1980s, MV had been provided in community campaigns and not in routine service and vaccination status depended on whether the mother had been around at the time of the campaign and not on bias. In the studies that adjusted for background factors, the differential effect of vaccination on the measles case death was actually increased. Furthermore, several studies have found that ‘vaccine failures’ occur after high intensity of vaccination campaigns.

### Table 4: Measles case death ratio for infants and older children in African prospective community studies and community surveys

<table>
<thead>
<tr>
<th>Country</th>
<th>Period</th>
<th>Type of study</th>
<th>Infants, % (deaths/cases)</th>
<th>Children 1+ year, % (deaths/cases)</th>
<th>Measles case death ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Studies before the introduction of MV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gambia</td>
<td>1961</td>
<td>PCS; rural</td>
<td>31 (12/39)</td>
<td>13 (47/356)</td>
<td>2.33 (1.36–4.00)</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>1979</td>
<td>PCS; rural</td>
<td>28 (22/79)</td>
<td>14 (55/380)</td>
<td>1.92 (1.25–2.96)</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>1980</td>
<td>PCS; rural</td>
<td>47 (7/15)</td>
<td>21 (31/147)</td>
<td>2.21 (1.18–4.13)</td>
</tr>
<tr>
<td>Senegal</td>
<td>1983–1986</td>
<td>PCS; rural</td>
<td>12 (19/165)</td>
<td>6 (79/1355)</td>
<td>1.95 (1.21–3.13)</td>
</tr>
<tr>
<td><strong>Studies after introduction of MV</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kenya</td>
<td>1974–1976</td>
<td>PCS; rural</td>
<td>6 (4/63)</td>
<td>7 (24/361)</td>
<td>0.96 (0.34–2.66)</td>
</tr>
<tr>
<td>Kenya</td>
<td>1976–1977</td>
<td>PCS; rural</td>
<td>4 (5/125)</td>
<td>1 (7/540)</td>
<td>3.09 (1.00–9.56)</td>
</tr>
<tr>
<td>Kenya</td>
<td>1986</td>
<td>SUR; rural</td>
<td>17 (5/29)</td>
<td>7 (8/110)</td>
<td>2.37 (0.84–6.71)</td>
</tr>
<tr>
<td>Senegal</td>
<td>1988</td>
<td>SUR; rural</td>
<td>22 (9/41)</td>
<td>5 (11/207)</td>
<td>4.13 (1.83–9.33)</td>
</tr>
<tr>
<td>Senegal</td>
<td>1989–1990</td>
<td>PCS; rural</td>
<td>2 (1/43)</td>
<td>2 (9/598)</td>
<td>1.55 (0.20–11.9)</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>1980–1982</td>
<td>PCS; urban</td>
<td>30 (7/23)</td>
<td>9 (10/115)</td>
<td>3.50 (1.49–8.24)</td>
</tr>
<tr>
<td>Guinea-Bissau</td>
<td>1983–1984</td>
<td>PCS; urban</td>
<td>9 (5/56)</td>
<td>7 (20/268)</td>
<td>1.20 (0.47–3.05)</td>
</tr>
<tr>
<td>Zaire</td>
<td>1974–1977</td>
<td>PCS; urban</td>
<td>6 (12/194)</td>
<td>6 (53/844)</td>
<td>0.99 (0.54–1.81)</td>
</tr>
<tr>
<td>Ghana</td>
<td>1989–1991</td>
<td>PCS; rural</td>
<td>21 (28/131)</td>
<td>15 (123/830)</td>
<td>1.44 (1.00–2.08)</td>
</tr>
<tr>
<td>Chad</td>
<td>1993</td>
<td>SUR; urban</td>
<td>6 (9/156)</td>
<td>8 (52/668)</td>
<td>0.74 (0.37–1.47)</td>
</tr>
<tr>
<td>Niger</td>
<td>2003</td>
<td>SUR; urban</td>
<td>16 (13/83)</td>
<td>9 (79/862)</td>
<td>1.71 (0.99–2.94)</td>
</tr>
<tr>
<td>Niger</td>
<td>1991–1992</td>
<td>PCS; rural</td>
<td>40 (16/40)</td>
<td>13 (65/488)</td>
<td>3.00 (1.93–4.67)</td>
</tr>
<tr>
<td>Niger</td>
<td>2003–2004</td>
<td>SUR; urban</td>
<td>7 (8/111)</td>
<td>3 (22/656)</td>
<td>2.15 (0.98–4.71)</td>
</tr>
<tr>
<td>Chad</td>
<td>2004–2005</td>
<td>SUR; urban</td>
<td>5 (5/97)</td>
<td>2 (15/609)</td>
<td>2.09 (0.78–5.63)</td>
</tr>
<tr>
<td>Nigeria</td>
<td>2004–2005</td>
<td>SUR; urban</td>
<td>11 (5/47)</td>
<td>7 (75/1095)</td>
<td>1.55 (0.66–3.66)</td>
</tr>
<tr>
<td>Zimbabwe</td>
<td>1980–1989</td>
<td>SUR; rural</td>
<td>13 (13/103)</td>
<td>3 (15/534)</td>
<td>4.49 (2.20–9.16)</td>
</tr>
<tr>
<td>Sudan</td>
<td>2004</td>
<td>SUR</td>
<td>3 (1/36)</td>
<td>1 (9/1108)</td>
<td>3.42 (0.45–26.28)</td>
</tr>
<tr>
<td><strong>Longer follow-up than 1 month</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burundi</td>
<td>1989</td>
<td>SUR; rural</td>
<td>14 (2/176)</td>
<td>6 (20/3816)</td>
<td>2.17 (0.51–9.20)</td>
</tr>
<tr>
<td>Gambia</td>
<td>1981</td>
<td>SUR; rural</td>
<td>64 (7/11)</td>
<td>10 (13/124)</td>
<td>6.07 (3.07–12.0)</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.87 (1.63–2.14)</td>
</tr>
</tbody>
</table>

Sources: Reviews of measles case death studies and PubMed search for community studies of measles mortality/case death in infants or by age in Africa. The age grouping is 7–12 months and 12–120 months. Measles deaths and total number of children in age group were reported in this study. It has been assumed that all children between 7 and 120 months contracted measles. In this period, there were no measles vaccinations available. The last epidemic had occurred 12–13 years earlier. The age grouping is 0–9 and 9+ months. MV, measles vaccine; PCS, prospective community study, that is, the population was known before the epidemic and information is likely to have been obtained for all children; SUR, retrospective survey.
exposure, that is, ‘vaccine failures’ are more likely to be secondary cases exposed at home. Since secondary cases have a higher case death than index cases, the milder infection among vaccinated children is even more surprising. The possibility that measles-vaccinated children have milder disease due to modified immune responses and not merely due to social confounding is strengthened by the many studies showing that measles infections are more severe in infancy, but on the other hand, modification of severity by maternal antibodies could have reduced the case death among infants.

Several hospital- or health centre-based studies have also compared vaccinated and unvaccinated children and reported that measles-vaccinated children had less severe measles infection. A few community studies from India and Papua New Guinea have also suggested lower case death for vaccinated measles cases.

If the severity of measles is not the same in vaccinated and unvaccinated children, it would strongly affect the estimated benefit of vaccinations at different ages.

**Assumption 4: severity of measles is the same whether measles infection is acquired in infancy or later**

**Background**

In the hypothetical EPI model in which all children were vaccinated at a specific age, the unvaccinated measles cases would occur in infancy, before measles vaccination, whereas most ‘vaccine failures’ would occur much later after the first year of life. No adjustment was made for how this affected the overall measles mortality. Most infections are more severe in infancy, but on the other hand, modification of severity by maternal antibodies could have reduced the case death among infants.

**Data**

We therefore searched for studies of ‘measles case fatality’ (N=161) and ‘measles mortality/death Africa’ (N=620). We found 24 relevant studies (table 4).

**Analysis**

The African community studies reporting the measles case death separately for infants and older children have been presented in table 4. One review of East African studies of measles have previously emphasised that the case death was particularly high in infants. However, a comparative analysis of the measles case death for infants and older children in all African community studies have not been made before. With a few exceptions, the studies suggested that the case death is higher in infancy than among older children (table 4). These studies suggest around a twofold higher measles case death in infancy; the MH weighted case death ratio for all studies was 1.87 (1.63–2.14). The effect was similar before MV was introduced in these communities

---

**Table 5** Vaccine efficacy against overall mortality for one dose of standard-titre measles vaccine before 9 months of age

<table>
<thead>
<tr>
<th>Country</th>
<th>Period</th>
<th>Comparison</th>
<th>Results (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early measles vaccination at 7 months of age compared with children unvaccinated community</td>
<td>Congo¹¹ 1974–1977</td>
<td>MV administered at 7 months of age; children followed to 21 and 34 months of age. Mortality from 7 to 21 months of age for vaccinated children (3205 person-years) compared with unvaccinated children from control area (21470.7 person-years)</td>
<td>MRR for 7–21 months =0.29 (0.09–0.98) and MRR for 7–34 months =0.52 (0.21–1.27)</td>
</tr>
<tr>
<td>Comparing MV at 4–8 months vs MV at 9–11 months of age</td>
<td>Guinea-Bissau ¹⁷ 1980–1982</td>
<td>Natural experiment: MV at 4–8 months vs MV at 9–11 months compared from 9 to 60 months of age</td>
<td>MRR (MV 4–8 months/MV 9–11 months) 0.69 (0.46–1.08)</td>
</tr>
<tr>
<td>Comparing children randomised to MV at 6 months vs IPV at 6 months during a war situation</td>
<td>Guinea-Bissau ¹⁸ 1998</td>
<td>Children were randomised to MV (4214) or inactivated polio vaccine (11219) at 6 months of age. Due to a war, they did not receive the planned MV at 9 months. Follow-up for 3 months in a war situation</td>
<td>70% (13–92)</td>
</tr>
</tbody>
</table>

Sources: All studies examining the general effect of standard measles vaccine (MV) on child survival (as compiled by all available reviews) have been screened for information on measles vaccination before 9 months of age. There have been several other studies of the impact of MV before 12 months of age on child survival but most of these studies could not distinguish the effect of MV before 9 months of age. However, all studies suggested that early MV had a better effect on child survival than later MV. The studies where children received diphtheria–pertussis–tetanus or inactivated polio vaccine (IPV) with early MV or shortly after MV have not been included in the present table since these studies have not been made before. With a few exceptions, the studies suggested that the case death is higher in infancy than among older children (table 4). These studies suggest around a twofold higher measles case death in infancy; the MH weighted case death ratio for all studies was 1.87 (1.63–2.14). The effect was similar before MV was introduced in these communities.

---
Optimal age of measles vaccination

Considerations
Only three studies did not show higher case death in infancy, and half the studies showed significantly higher mortality in infancy. Even if a few studies should not have been found by the search terms, it seems unlikely that additional studies would change the tendency.

If the case death is indeed higher in infancy, it would be more advantageous to have vaccine failures later in life rather than leave infants <9 months of age unprotected.

Assumption 5: vaccine failures lead to lack of credibility of the vaccination programme

Background
Apparently it was assumed that African mothers—like physicians—would lose confidence if MV did not provide complete and lifelong immunity.

Data
We searched ‘measles vaccine failure’ (N=318) and ‘measles vaccine/vaccination/immunisation credibility’ (N=2). This search produced one paper dealing with the relationship between ‘vaccine failure’ and the acceptance or credibility of measles vaccination.81 One study was known from our own research.32

Analysis
One study from Tanzania stated that acceptance of measles vaccination was low because of the many failures experienced by children vaccinated before 9 months of age.

In the only community study, which examined the credibility of the programme in relation to previous experiences with ‘vaccine failures’, younger siblings of ‘vaccine failures’ had a significantly higher coverage for measles vaccination (95% (33/35)) than siblings of children who had been successfully vaccinated and not had measles infection (78% (630/809)). Hence, the younger siblings of ‘vaccine failures’ were significantly more likely to have been measles vaccinated (RR=1.21 (1.11–1.32)).32

Considerations
The study from Tanzania provided no specific information on how data had been collected and how low acceptance had been measured.81 In contrast to this negative view of measles vaccination, many African mothers have experienced that vaccinated children have mild measles infection.32 In cultures where mothers have learnt that everybody has to get measles, the advantage of ‘mild measles’ is easy to see, whereas it is difficult to ‘see’ complete ‘lifelong protection’ if you still expect your child will get measles some day. Hence, it may have worked the other way around; seeing your child get mild measles after vaccination would be a strong argument for the value of measles vaccination.

Assumption 6: it had to be a one-dose policy

Background
The main argument advanced for a one-dose policy was that compliance with the second dose was too low.15 18 32 82 This is surprising since it has been described that mothers sought vaccination so eagerly that it was impossible to maintain the age eligibility criteria for vaccinations during campaigns.16 The reason why mothers did not seek the second dose of MV in some countries may have been poor information. In Guinea-Bissau, we had very good compliance and improved overall coverage with a two-dose schedule.83 The two-dose group had better protection against measles infection than the one-dose group.83 A two-dose schedule has also been shown to be effective in Niger,84 India35 and Saudi Arabia.86 Hence, a two-dose schedule is both feasible and effective.

Data
To identify studies comparing the effect on survival of a one-dose and a two-dose policy, we used the reviews of measles vaccination and impact on mortality30 53 54 and searched papers on ‘Two/2 dose measles vaccine trial’ (N=144), ‘Two/2 dose measles vaccination/immunisation and mortality/death’ (N=108) and ‘early measles vaccination/immunisation mortality/death’ (N=123). These procedures identified only two trials of the effect on child survival of a two-doses measles vaccinations schedule compared with a one-dose schedule (see table 6) and one observational study.57

Analysis
Only two trials have compared child mortality following two doses of MV (the first being given before 9 months) with mortality after the standard dose of MV (at 9 months of age) (table 6). In a small trial from Sudan,87 diphtheria—pertussis—tetanus (DTP) vaccinations were not controlled and many children received DTP after MV. DTP administered with or after MV has negative effects on female survival.55 68 We therefore conducted a large randomised trial including only children who had received DTP3 before enrolment and therefore would not receive DTP after MV.88 Among children who had not received neonatal vitamin A supplementation which interacted negatively with early MV,88 two doses of MV at 4.5 and 9 months of age compared with the current policy of one dose at 9 months of age reduced mortality between 4.5 and 36 months of age by 50% (22%–68%) in the per-protocol analysis (table 6). There was a significant reduction in non-measles-related mortality of 45% (14%–65%).88 The combined estimate for the two trials showed that the early two-dose measles vaccination strategy may reduce mortality by as much as 48% (23%–65%) compared with the currently recommended standard dose at 9 months of age. Even if the children receiving neonatal vitamin A supplementation were included, the combined estimate was 31% (9%–48%) (table 6).


(MH weighted case death ratio=2.04 (1.58–2.63)) (see studies before the introduction of MV, table 4).

Assumption 5: vaccine failures lead to lack of credibility of the programme

Background
Apparently it was assumed that African mothers—like physicians—would lose confidence if MV did not provide complete and lifelong immunity.

Data
We searched ‘measles vaccine failure’ (N=318) and ‘measles vaccine/vaccination/immunisation credibility’ (N=2). This search produced one paper dealing with the relationship between ‘vaccine failure’ and the acceptance or credibility of measles vaccination.81 One study was known from our own research.32

Analysis
One study from Tanzania stated that acceptance of measles vaccination was low because of the many failures experienced by children vaccinated before 9 months of age.

In the only community study, which examined the credibility of the programme in relation to previous experiences with ‘vaccine failures’, younger siblings of ‘vaccine failures’ had a significantly higher coverage for measles vaccination (95% (33/35)) than siblings of children who had been successfully vaccinated and not had measles infection (78% (630/809)). Hence, the younger siblings of ‘vaccine failures’ were significantly more likely to have been measles vaccinated (RR=1.21 (1.11–1.32)).32

Considerations
The study from Tanzania provided no specific information on how data had been collected and how low acceptance had been measured.81 In contrast to this negative view of measles vaccination, many African mothers have experienced that vaccinated children have mild measles infection.32 In cultures where mothers have learnt that everybody has to get measles, the advantage of ‘mild measles’ is easy to see, whereas it is difficult to ‘see’ complete ‘lifelong protection’ if you still expect your child will get measles some day. Hence, it may have worked the other way around; seeing your child get mild measles after vaccination would be a strong argument for the value of measles vaccination.

Assumption 6: it had to be a one-dose policy

Background
The main argument advanced for a one-dose policy was that compliance with the second dose was too low.15 18 32 82 This is surprising since it has been described that mothers sought vaccination so eagerly that it was impossible to maintain the age eligibility criteria for vaccinations during campaigns.16 The reason why mothers did not seek the second dose of MV in some countries may have been poor information. In Guinea-Bissau, we had very good compliance and improved overall coverage with a two-dose schedule.83 The two-dose group had better protection against measles infection than the one-dose group.83 A two-dose schedule has also been shown to be effective in Niger,84 India35 and Saudi Arabia.86 Hence, a two-dose schedule is both feasible and effective.

Data
To identify studies comparing the effect on survival of a one-dose and a two-dose policy, we used the reviews of measles vaccination and impact on mortality30 53 54 and searched papers on ‘Two/2 dose measles vaccine trial’ (N=144), ‘Two/2 dose measles vaccination/immunisation and mortality/death’ (N=108) and ‘early measles vaccination/immunisation mortality/death’ (N=123). These procedures identified only two trials of the effect on child survival of a two-dose measles vaccinations schedule compared with a one-dose schedule (see table 6) and one observational study.57

Analysis
Only two trials have compared child mortality following two doses of MV (the first being given before 9 months) with mortality after the standard dose of MV (at 9 months of age) (table 6). In a small trial from Sudan,87 diphtheria—pertussis—tetanus (DTP) vaccinations were not controlled and many children received DTP after MV. DTP administered with or after MV has negative effects on female survival.55 68 We therefore conducted a large randomised trial including only children who had received DTP3 before enrolment and therefore would not receive DTP after MV.88 Among children who had not received neonatal vitamin A supplementation which interacted negatively with early MV,88 two doses of MV at 4.5 and 9 months of age compared with the current policy of one dose at 9 months of age reduced mortality between 4.5 and 36 months of age by 50% (22%–68%) in the per-protocol analysis (table 6). There was a significant reduction in non-measles-related mortality of 45% (14%–65%).88 The combined estimate for the two trials showed that the early two-dose measles vaccination strategy may reduce mortality by as much as 48% (23%–65%) compared with the currently recommended standard dose at 9 months of age. Even if the children receiving neonatal vitamin A supplementation were included, the combined estimate was 31% (9%–48%) (table 6).
<table>
<thead>
<tr>
<th>Country and period</th>
<th>Age interval</th>
<th>Comparison (vaccines)</th>
<th>Administration of DTP</th>
<th>Deaths/person-years or persons</th>
<th>Mortality rate ratio (95% CI)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sudan87 1989–1992</td>
<td>5–9 months</td>
<td>MV vs control (Meningococcal A + C)</td>
<td>DTP not given simultaneous with MV but could have been given after MV</td>
<td>1/60.5 vs 6/61.2</td>
<td>0.18 (0.02–1.54)</td>
<td>1st vaccine in 2-dose group was Connaught HTMV and 2nd dose was Schwarz standard MV</td>
</tr>
<tr>
<td></td>
<td>9–36 months</td>
<td>2nd vs 1st MV</td>
<td>DTP not given simultaneous with MV and after MV; all had DTP3 1 month before enrolment</td>
<td>7/371.6 vs 7/355.9</td>
<td>0.96 (0.34–2.73)</td>
<td>Vitamin A supplementation (VAS) at birth is not official policy. Hence, only results for children who did not receive VAS are presented*</td>
</tr>
<tr>
<td></td>
<td>4.5–9 months</td>
<td>MV vs control (no vaccine)</td>
<td>5/398.8 vs 29/821.8</td>
<td></td>
<td>0.33 (0.13–0.86)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>9–36 months</td>
<td>2nd vs 1st MV</td>
<td>20/2054.4 vs 67/3881.1</td>
<td>0.56 (0.34–0.93)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4.5–36 months</td>
<td>5–36 months</td>
<td></td>
<td>0.50 (0.32–0.78)*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guinea-Bissau88 2003–2009</td>
<td>5–36 months</td>
<td>MV vs control</td>
<td>DTP not given simultaneous with MV and after MV; all had DTP3 1 month before enrolment</td>
<td>5/398.8 vs 29/821.8</td>
<td>0.33 (0.13–0.86)</td>
<td>Vitamin A supplementation (VAS) at birth is not official policy. Hence, only results for children who did not receive VAS are presented*</td>
</tr>
</tbody>
</table>

Source: All studies reporting mortality in trials of two doses of measles vaccine (MV). Only per-protocol results have been used comparing children who received two doses of MV with those receiving one dose at 9 months. No additional studies of early two-dose measles vaccination reporting impact on mortality were found by PubMed searches. The combined estimate (Stata) was 0.50 (0.35–0.77); if the children receiving vitamin A at birth were also included, the combined estimate was 0.69 (0.52–0.91).

* The combined estimate (Stata) was 0.52 (0.35–0.77); if the children receiving vitamin A at birth were also included, the combined estimate was 0.69 (0.52–0.91).

DTP, diphtheria–pertussis–tetanus.

The main justification for measles vaccination at 9 months of age in low-income countries was to reduce child mortality from measles infection. However, the optimal age of MV in terms of reducing measles mortality (table 1, columns 7–10). Using the best estimate that the case death rate is threefold lower for vaccinated cases than unvaccinated cases (tables 2 and 3), the number of estimated measles deaths would have been lowest with one dose of MV at 8 months (column 7). Assuming, furthermore, that children have twofold higher case death than older children (table 4), the estimated number of measles deaths would have been lowest with one dose of MV at 8 months (column 7). Hence, early vaccination at age 7 months (column 8) might have been better to vaccinate at age 7 months rather than to have many unvaccinated cases in childhood and then to have many more vaccine failures later in childhood than to have many more vaccine failures later in childhood than to have many more vaccine failures.”

**DISCUSSION**

The studies indicate that an early dose of MV before 9 months of age is associated with major reductions in child mortality compared with the current one dose at 9-month policy. The studies indicate that the benefit was not due to better protection against measles infection. Hence, these studies strongly supported that early measles vaccination has non-specific beneficial effects on child survival. Considerations

The only other study to report mortality after two doses of MV is a hospital-based study from Ghana in 1990. Children were vaccinated in annual campaigns rather than through routine service or biannual campaigns rather than through routine service or biannual campaigns. The estimated number of measles deaths would have been lowest with one dose of MV at 8 months (column 7). Assuming, furthermore, that children have twofold higher case death than older children (table 4), the estimated number of measles deaths would have been lowest with one dose of MV at 8 months (column 7). Hence, early vaccination at age 7 months (column 8) might have been better to vaccinate at age 7 months rather than to have many unvaccinated cases in childhood and then to have many more vaccine failures later in childhood than to have many more vaccine failures later in childhood than to have many more vaccine failures later in childhood than to have many more vaccine failures.”

**The implications of the assumptions for the estimated prevention of measles mortality**

The first dose of MV before 9 months of age is associated with major reductions in child mortality compared with the current one dose at 9-month policy. The studies indicate that the benefit was not due to better protection against measles infection. Hence, these studies strongly supported that early measles vaccination has non-specific beneficial effects on child survival.
policy was never tested for its effect on survival. The policy was based on assumptions, which were believed to be true, and a small seroconversion study. Thirty-five years ago, the six assumptions appeared self-evident and programmatic decisions had to be taken about the optimal age for measles vaccination. However, though all assumptions have been contradicted for years, no change has been made in the policy.

**Strength and weaknesses**

Since the six assumptions have not been research issues, there are few studies conducted specifically with these topics in mind. We have therefore had to use a search strategy including review articles and case reports to find studies to assess the validity of the original assumptions. The literature search and assessment was only carried out by one researcher who has followed the topic of measles mortality and measles vaccination in Africa for more than 30 years. There may be a few more studies that were not found with the literature search since several of the studies identified in previous reviews were not found by the search terms. However, many reviews over the last 25 years have covered the areas of community studies of measles infection and the impact of MV on mortality so it is unlikely that there would be many studies not included. Furthermore, the estimates from different studies were consistent and it is unlikely that the addition of further studies would have a major impact on the estimates.

The assumed case death of measles infection does not matter for the estimated impact of the optimal policy on measles mortality. With another case death level, the epidemiological arguments about assumptions two to four would still have the same relative effects on the number of deaths prevented. However, as evident in tables 2 and 4, most community studies from Africa suggest that the case death may have been higher than 4% and the impact of the optimal measles vaccination strategy on overall mortality may therefore have been even larger. Other assumptions may also have been important; for example, the incidence data were from a rural study rather than from an urban area. In an urban area, the incidence would have been higher at younger ages and it might have been advantageous to vaccinate even earlier. As maternal measles antibody levels have declined in low-income countries, earlier vaccination would also have produced better seroconversion rates and it would have been even more advantageous to vaccinate early.

**Consistency with previous studies: the non-specific beneficial effects of MV**

The conclusion that earlier measles vaccination is likely to have been better for child survival is based on a reconsideration of the programme’s own assumptions about effect on measles mortality. However, what is the empirical evidence for the impact on mortality of MV before 9 months of age? In marked contradiction to the original fear that children dying of measles would just die of something else and that measles vaccination would therefore only change the cause of death but not the level of mortality, all subsequent studies measuring the effect on survival have found marked benefit from measles vaccination. Several studies have assessed the impact of MV before 12 months of age but few studies have separately measured the effect on overall mortality of measles vaccination before 9 months of age in an unbiased way (table 5). In the 1970s, researchers in Congo followed two districts, which initially had similar overall mortality levels and then introduced measles vaccination at 7 months of age in one district. Measles vaccination administered at 7 months of age reduced overall mortality between 7 and 21 months of age by 71% (2%–91%) compared with the neighbouring district that did not get measles vaccination. In the early 1980s in Guinea-Bissau, children were vaccinated in annual or biannual campaigns. Hence, it was possible to compare in a ‘natural experiment’ manner the survival of children who had been measles vaccinated before 9 months of age and those vaccinated at 9 months of age, the recommended age of measles vaccination. One dose of MV at 4–8 months compared with 9–11 months of age was associated with 31% (−8% to 54%) lower mortality between 9 months and 5 years of age. As mentioned above, the effect was even stronger if they also received a second dose of MV after 9 months of age. During a civil war in Guinea-Bissau in 1998, we followed children who had been randomised to measles vaccination at 6 months of age compared with children who had been randomised to inactivated polio vaccine. Due to the war, the children did not get the standard measles vaccination at 9 months of age. During the 3 months of intensive fighting when everybody had fled the study area and mortality was high, the children vaccinated against measles at 6 months of age had 70% (13%–92%) lower mortality than the unvaccinated group.

These studies of one dose of MV before 9 months of age as well as the studies of early two-dose MV mentioned above suggest that the reduction in mortality from MV before 9 months of age is much larger than can be explained by the prevention of measles infection. WHO estimates that measles deaths caused 10% of under-5 deaths. However, all available studies of the mortality impact of MV suggest that the effect of measles immunisation on mortality is much greater than expected. This beneficial effect is a consistent observation and it cannot be explained by the prevention of acute measles infection. First, all studies, in which MV was not administered with DTP, provided strong evidence of a beneficial effect of MV on overall mortality. Second, all studies censoring for measles infection in the survival analysis to estimate the impact on non-measles-related mortality found that prevention of measles-specific deaths explained little and the beneficial effect was due to prevention of...
non-measles-related mortality. For example, in the per-protocol analysis of the largest randomised trial, MV at 4.5 and 9 months compared with the standard dose at 9 months of age reduced non-measles-related mortality significantly for all children. Third, the beneficial effect of MV is usually stronger for girls than for boys. Since measles mortality is not higher for girls than boys, this observation suggests sex-differential mechanisms related to immune stimulation. Hence, standard MV may protect against other infections and have a beneficial effect on child survival even when measles is eliminated.

Though the focus here has been on MV administered before 9 months of age, there is also a considerable number of studies indicating that MV administered after 9 months of age have non-specific beneficial effects. The possible biological explanations for non-specific beneficial effects of MV have not been explored in humans. In animal studies of heterologous immunity, previous stimulation with infections may have a major effect on the capacity to handle a lethal dose of an unrelated infection. Two trials from Bissau suggest that the beneficial effect of MV is better for children vaccinated in the presence of maternal measles antibodies than for children having no measurable maternal antibodies at the time of MV (unpublished data). This may also help explain why MV before 9 months of age is better than later vaccination.

**The optimal age of measles vaccination: optimising seroconversion or impact on overall child survival**

The most unfortunate consequence of not testing the optimal age of measles immunisation may have been that the beneficial non-specific effects of MV were not detected. To the extent MV has beneficial non-specific effects, the question of the optimal age of measles vaccination acquires a new meaning. By lowering the age of measles vaccination, children would benefit from earlier protection against measles infection and from the beneficial non-specific effects against non-measles infections and overall child mortality would be reduced. On the other hand, if the age of vaccination is increased, children would benefit less from the beneficial non-specific effects and overall child mortality would increase. Hence, policies optimising the non-specific effects clash with those designed to enhance seroconversion.

**Conclusions: old assumptions linger on**

The supplementary immunisation activities with MV has eliminated measles infection in Latin America and reduced the incidence in major ways in the rest of the world. The world is now planning to eliminate and eventually eradicate measles infection. With the supplementary immunisation activities success in measles control, the optimal age of measles immunisation is likely to be considered an irrelevant issue. However, as discussed above, MV has also non-specific effects, which need to be taken into consideration in the planning of vaccination programmes. The prevention of all-cause mortality rather than measles mortality should be the primary objective. In a culture that advocates evidence-based policies, the evidence for the current measles vaccination policy—or rather the lack thereof—should be properly reviewed and revised by the global and regional immunisation programmes. Otherwise old assumptions about seroconversion rates being the basis for the optimal age of immunisation may linger on and continue to influence policy.

There are major consequences of focusing solely on specific measles mortality. First, as the current policy is mostly determined by our understanding that seroconversion gets better with increasing age, the tendency will be that with improved control of measles infection, age of vaccination will be increased. Following the elimination of measles in Latin America, the recommended age of primary measles immunisation was raised to 12 months in 1996. Again this decision was based on assumptions and not on studies documenting the overall effect on morbidity and mortality. Following the success of measles campaigns in other continents, it has also been recommended by SAGE (the Strategic Advisory Group of Experts) to increase the age of measles vaccination to 12 months in areas with low levels of measles transmission. The underlying assumption about better seroconversion at higher ages may no longer be valid with the decline in maternal antibody levels. For example, we have obtained 100% seropositivity and 99% protective levels after MV at 9 months of age with both Schwarz and Edmonston-Zagreb MV strains in Guinea-Bissau.

However, the most important problem is that MV has major non-specific beneficial effects, and the earlier it is given, the earlier the children will benefit from this advantage. There is a tendency to dismiss these observations because randomised trials with overall mortality as an outcome have only been conducted in Guinea-Bissau and it is therefore claimed that the global health community has to wait for verification elsewhere. However, the beneficial non-specific effects of MV have been shown in several other countries with high childhood mortality. For example, in a crossover design, Shann showed that girls receiving standard MV at 9–10 months of age in five randomised trials in Sudan, Gambia, Senegal and Guinea-Bissau had 47% lower mortality through childhood than control children who received an inactivated vaccine at 9–10 months of age. Since the control children had received MV before 9 months of age and did not get measles, the difference in mortality following MV at 9 months of age was a beneficial non-specific effect not related to prevention of measles infection. Increasing the age of MV from 9 to 12 months may reduce the beneficial effects in the age group between 9 and 12 months of age in which mortality is still high. Thus, the lives lost by this
change of schedule could well be more than the lives saved by improved measles control.88

Second, in the current paradigm for control of infectious diseases, the ultimate success in public health is to eradicate the disease and then remove the vaccine to reduce economic costs as happened for smallpox in the 1970s.26 This may happen for measles infection within the next 10–20 years.56 If MV has major beneficial non-specific effects,88 to remove MV or reduce its coverage would increase child mortality levels considerably in low-income countries unless we in the meantime find a vaccine which has all the same beneficial effects as MV.

After 35 years, it is time to develop a policy for the optimal age of measles immunisation. This policy needs to be based on evidence about the impact on overall health and child survival and not only on assumptions about the impact of specific prevention against measles infection. A two-dose measles vaccination strategy, providing MV at 4.5 months of age, after the three DTP vaccines and again at 9 months of age, may significantly improve child survival and provide a solid basis of immunity which if necessary can be enhanced by supplementary measles immunisation activities at a later age.58 59 Any future changes in the age of measles immunisation due to elimination of measles infection, changes in the epidemiology of measles infection, decline in maternal antibody levels, introduction of new MVs or in the timing of other vaccines should be tested in trials to determine their overall impact on child health.

Author affiliations
1 Bandim Health Project, Indepth Network, Bissau, Guinea-Bissau
2 Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Danish Epidemiology Science Centre, Statens Serum Institut, Copenhagen S, Denmark
3 London School of Hygiene and Tropical Medicine, London, UK

Contributors PA, CB and HW planned the present study. The first of many drafts was written by PA and all authors contributed critically to the refinement of the arguments and the final version of the paper. All authors approved the final version of the paper. PA will act as guarantor of the study.

Funding The Bandim Health Project received support from the DANIDA and the Danish National Research Foundation. PA holds a research professorship grant from the Novo Nordisk Foundation. CSB holds an ERC Starting Grant (ERC-Sig-243149). We received no funding specifically for the present study.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data available.

REFERENCES


Optimal age of measles vaccination


